Provides basic information to direct care providers at the state level as they address Fed. regulatory procedures for the development and management of narcotic treatment programs. Presents information about state and Fed. application requirements for program approval and compliance with ongoing regulatory standards. Also serves as a reference for Fed. agencies and state authorities involved in program oversight, management, and technical assistance. Includes FDA and DEA forms and regulations, confidentiality reg's., standard definitions used during application and monitoring, investigational new drug application reg's.

Prepared to facilitate the transfer of state-of-the-art protocols and guidelines for the treatment of alcohol and other drug (AOD) abuse from acknowledged clinical, research, and administrative experts to the Nation's AOD abuse treatment resources. Includes: introduction on LAAM (levo-alpha-acetyl-methadol), which suppresses opiate withdrawal symptoms for more than 72 hours; clinical profile of LAAM; clinical application of LAAM therapy; treatment planning; management and administrative issues; and regulatory and ethical issues. Bibliography. Training resources.

Pharmacotherapy, as a means of treating drug addiction in combination with other treatment modalities, has received too little attention from the research community, the pharmaceutical industry, public health officials, and the federal government. Medications to combat drug addiction could have an enormous impact on the medical consequences and socioeconomic problems associated with drug abuse, both for drug-dependent individuals and for American society as a whole. This book examines the current environment for and obstacles to the development of anti-addiction medications, specifically those for treating opiate and cocaine addictions, and proposes incentives for the pharmaceutical industry that would help overcome those obstacles and accelerate the development of anti-addiction medications.